Tandem Diabetes Care (NASDAQ:TNDM) Given New $36.00 Price Target at Robert W. Baird

Tandem Diabetes Care (NASDAQ:TNDM) had its price objective raised by analysts at Robert W. Baird from $28.00 to $36.00 in a report issued on Friday, Benzinga reports. The brokerage currently has a “neutral” rating on the medical device company’s stock. Robert W. Baird’s price objective points to a potential downside of 15.83% from the company’s current price.

Other equities analysts also recently issued reports about the stock. Wells Fargo & Company raised shares of Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $21.00 to $45.00 in a report on Monday. SVB Leerink upgraded Tandem Diabetes Care from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $34.00 to $45.00 in a research note on Thursday, April 25th. StockNews.com upgraded Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research report on Friday, April 19th. Stifel Nicolaus boosted their price target on Tandem Diabetes Care from $37.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, April 23rd. Finally, Citigroup increased their price objective on Tandem Diabetes Care from $31.00 to $38.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. One analyst has rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $41.18.

Tandem Diabetes Care Stock Performance

NASDAQ TNDM opened at $42.77 on Friday. The firm has a market capitalization of $2.76 billion, a P/E ratio of -10.63 and a beta of 1.10. Tandem Diabetes Care has a fifty-two week low of $13.82 and a fifty-two week high of $42.77. The stock has a 50-day simple moving average of $31.98 and a two-hundred day simple moving average of $25.90. The company has a debt-to-equity ratio of 0.91, a quick ratio of 3.02 and a current ratio of 3.83.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its earnings results on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Tandem Diabetes Care had a negative net margin of 29.77% and a negative return on equity of 31.48%. The firm had revenue of $196.80 million for the quarter, compared to analysts’ expectations of $204.86 million. On average, equities analysts forecast that Tandem Diabetes Care will post -1.62 earnings per share for the current year.

Institutional Investors Weigh In On Tandem Diabetes Care

Hedge funds and other institutional investors have recently bought and sold shares of the company. RiverPark Advisors LLC purchased a new stake in shares of Tandem Diabetes Care during the 4th quarter valued at approximately $27,000. MCF Advisors LLC raised its holdings in shares of Tandem Diabetes Care by 79.3% in the 1st quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock valued at $36,000 after buying an additional 445 shares during the period. Signaturefd LLC lifted its position in shares of Tandem Diabetes Care by 871.8% during the fourth quarter. Signaturefd LLC now owns 1,691 shares of the medical device company’s stock worth $50,000 after purchasing an additional 1,517 shares in the last quarter. Arcadia Investment Management Corp MI boosted its position in Tandem Diabetes Care by 141.6% in the 1st quarter. Arcadia Investment Management Corp MI now owns 1,851 shares of the medical device company’s stock valued at $66,000 after buying an additional 1,085 shares during the period. Finally, PNC Financial Services Group Inc. increased its holdings in Tandem Diabetes Care by 51.7% during the 3rd quarter. PNC Financial Services Group Inc. now owns 3,226 shares of the medical device company’s stock worth $67,000 after purchasing an additional 1,099 shares during the period.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.